Why Sandoz Group Rose Even Though Profit Fell
If you only glanced at Sandoz Group’s latest half year figures, with revenue higher but net income much lower, you might not expect a strong payoff for patient holders. For Sandoz Group shareholders, the return over the past year was 58.8%, including dividends. That outcome landed despite legal settlements, a lost patent case on Spravato, and big spending on biosimilar expansion. If you were weighing Sandoz on 9 November 2025, what exactly made that kind of payoff a risk worth taking?
The move put Sandoz Group in the middle of this trade. Scan 127 healthcare AI stocks for other companies exposed to it.
The Two Sandoz Group Stories Investors Had To Weigh
Sandoz Group shares cost CHF52.88 at the start of the period, and you had to decide which story about the next few years felt more realistic.
On the optimistic side, the bullish case pointed to a Fair Value of CHF60.37, the price those projections implied if they played out. This scenario was built on revenue growth of 8.9% a year as healthcare systems shifted harder toward biosimilars.
The more cautious view put Fair Value at CHF49.39 and treated 6.3% yearly revenue growth as the ceiling. In this case, pressure on pricing and heavy reliance on partnerships were seen as key risks to long term margins.
What The Evidence Did To The Sandoz Group Story
Sandoz Group spent the period leaning into biosimilars, from a broad collaboration with Henlius to an emicizumab deal with mAbxience and Brazil approval for semaglutide product Owozy, which supported the optimistic volume story. The hard numbers told a tougher tale. Total revenue was US$5,265m in H1 2025 and US$5,784m in H1 2026, while net margin fell from 7.2% to 1.9%. Taken together, the evidence cut both ways.
The lesson here is simple. When a growth pitch rests on higher future profitability, you need to track net margin alongside new contracts and pipeline headlines. Then you can judge whether each extra dollar of sales is actually dropping to the bottom line.
What Sandoz Group's Run Up 59% Already Prices In
Today Sandoz Group trades at CHF84.46, well above the CHF52.88 starting point over the past year. The bearish analyst Narrative on Simply Wall St places its Fair Value below that level and anchors its caution in how capital heavy the Bio100 plan has become.
A buyer today effectively banks on Bio100 and the GLP 1 portfolio turning into strong, cash rich expansion. The question this Narrative raises is whether sustained high investment, regulatory friction and product specific legal outcomes let that play out smoothly enough.
"The main thing that has to go right is that Sandoz executes its capital intensive Bio100 and biosimilars expansion plan, including vertical integration and the European biosimilar hub, without eroding free cash flow or returns on invested capital."
One Narrative disagrees with today's price. → See where this Narrative says Sandoz Group should trade
Beyond Sandoz: Another Chronic Bet?
Sandoz Group leans on biosimilars and GLP 1 exposure to tell its story. Your next step could be thinking sideways, not just forward.
Chronic metabolic disease does not stop at one injectable. Patients, doctors and payers are also looking hard at pills, combinations and long term regimens.
Another large drug maker is trying to meet that demand. It is building an obesity and diabetes range that mixes injectables, oral treatments and combination therapies.
The same business is also pushing new cancer, neuroscience and immune system drugs. If it turns more conditions into chronic, treatable markets, that could reshape how you frame opportunity beside Sandoz Group.
One Narrative has already put a figure on it. → Uncover the company trading 14% below one Narrative's Fair Value
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com